Markets have been strong this week and, very importantly, the rally has been broad based and not just focused on the market leaders. Indeed, value stocks and smaller market cap stocks participated strongly.
The five largest stocks in the US account for some 20% of the value of the stock market. These stocks are Microsoft, Apple, Amazon, Alphabet (the parent of Google) and Facebook. Year to date this group is up 9% but the market is down by some 9%. Clearly the leadership has been very narrow and focused on these five largest stock.
This week however, the five market leaders were up by 4% and the overall market was up by 3%, so participation in the rally has widened out considerably. Banks were up by 10 % and even the oil sector was up by 15%. Finally, stocks that are less large – so-called small caps – were up by 6%. It is too early to tell if this is the start of a trend but at least this week it feels like the rally progressed from being a cautious rally to a less cautious one.
It is also worth bearing in mind that this participation by the wider market came during a week when tech company first quarter earnings were generally strong; products sold by the loosely defined ‘FAANG’ block have stood up and in many cases thrived amid the lockdown. Facebook is now seeing “signs of stability” after an initial steep decrease in March advertising revenue, while remote workers have been a boon for Microsoft’s cloud services.
On the virus front, all the data being tracked in this weekly update were positive this week. This morning the rate of change in new infections was 3% for the world ex-China, Germany’s rate was 1% and the UK’s 4%.
Furthermore, on Wednesday the US government’s top infectious disease expert, Anthony Fauci, said early results from the Gilead drug trial offered “quite good news”. Dr Fauci told reporters that Remdesivir was not a “knockout” but that he was “very optimistic”. Establishing that a drug can target a replication mechanism inside the virus can lead to other breakthroughs he said. Dr Fauci, compared this to his experience of the HIV epidemic, when a highly toxic drug known as AZT was first tested in the 1980’s, showing only a moderate benefit but that finding heralded breakthroughs in treatment.
Central banks also continued to make positive noises this week.
With all of this news, Let’s turn back to the Optimus Capital Coronavirus Checklist and see how far the world has come:
First, is the virus responding to lockdown measures? – Yes absolutely.
Second, is there the mass availability of testing? – In the US, weekly testing capacity now stands at roughly 2million. It probably needs to be at 4 million but the gap between current testing and needed testing is closing so this gets a tick.
Third, is there any good news on drug research? – As mentioned above, this week investors got news to cheer on this point but nothing concrete as of yet.
Finally, has policy response been strong? – One can only say yes to that. So there you have it. Most boxes on our list have been or are close to being ticked and so the world is looking at getting back to work. Yet as we look forward we admit to being surprised by how far and how fast stock markets have recovered. We would not be suprised to see things get a little choppier from here as economies start to deal with the realities of trying to reopen rather than just the thought experiment.
Risk Warnings
Please note that the investments referred to in this document are subject to market fluctuations, there can be no assurance that appreciation will occur and it may be possible that losses will be realised. Past performance is not necessarily a guide to future performance and the value of investments can fall as well as rise.
Disclaimer Optimus Capital LLP, a limited liability partnership registered in England and Wales with number OC348019, is authorised and regulated by the Financial Conduct Authority as Firm 506790. A list of members of Optimus Capital LLP together with those non-members who are designated as partners and their professional qualifications is open to inspection at its registered office 8th Floor, 116 Park Street, London, W1K 6SS. The information contained in this document has been compiled by Optimus Capital LLP and its affiliates and subsidiaries from sources believed by it to be reliable, but no representations or warranty, express or implied, is made by Optimus Capital LLP or any other person as to its accuracy, completeness or correctness. All opinions and estimates contained in this document constitute Optimus Capital LLP’s judgment as of the date of publishing, are subject to change without notice and are provided in good faith but without legal responsibility. The information in this document, which does not purport to be comprehensive, has not been verified by Optimus Capital LLP. The receipt of this document by any person is not to be taken as constituting the giving of investment advice by Optimus Capital LLP to any such person, nor to constitute such person as a client of Optimus Capital LLP. Unless otherwise agreed, Optimus Capital LLP will not regard any person as a client and will not be responsible for providing any protections afforded to clients of Optimus Capital LLP. Any person not a client of Optimus Capital LLP should seek independent advice on the suitability of the product referred to in this document. This document is not independent research and is intended as a financial promotion. The information has not been prepared in accordance with legal requirements required for independent research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The investments discussed in this report and strategies outlined in this document may not be eligible for sale in some jurisdictions and countries. Neither Optimus Capital LLP nor any of its affiliates and subsidiaries, nor any other person, accepts any liability whatsoever for any direct or consequential loss arising from any use of this document or the information contained herein. This material is not for distribution in the US. This document may not be reproduced, distributed or published by any recipient hereof for any purposes.
